Market Research Center has published a report on the size and trends of Japan's auto-injector market from 2026 to 2035. The market, valued at approximately US$108.86 million in 2025, is expected to expand to approximately US$492.79 million by 2035.
Japan's auto-injector market is expected to see significant growth, driven by the aging population and the spread of home healthcare. Demand is expected to broaden across applications, routes of administration and end-user segments, including prefilled and disposable devices.
The report estimates the market size at approximately US$108.86 million in 2025 and forecasts a CAGR of 16.3% for 2026-2035, with the market expected to reach approximately US$492.79 million by 2035. It expects demand for devices used in the long-term treatment of chronic diseases such as rheumatoid arthritis and diabetes to increase.
The approval and commercialization of new products are also supporting market growth. One example cited is the launch of sales of Metoject® Subcutaneous Injection by Eisai and 日本メダック in 2024. The report highlights the importance of device designs capable of handling high-viscosity drugs.
The spread of home healthcare, the development of connected devices with smart functions and the design of delivery mechanisms suited to drug characteristics are cited as future competitive factors. Major companies named in the report include Nipro, Terumo, Otsuka Pharmaceutical and SHL Medical Japan, with the development of combination products involving devices and drugs identified as important.